# Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks

> **NCT00147498** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 264 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** CP-690,550
- **DRUG:** CP-690,550
- **DRUG:** CP-690,550
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00147498
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2006-06
- **Final completion:** 2006-06
- **Target enrollment:** 264 (ACTUAL)
- **Last updated:** 2013-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00147498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00147498, "Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00147498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*